Adagene (ADAG) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Adagene (ADAG) has outperformed Tiziana Life Sciences (TLSA) over the past year, gaining 17.0% versus a loss of 46.2%. Over five years, TLSA leads with a -30.5% price change compared with -82.6% for ADAG. Adagene is the larger company by market cap ($138.3 million vs $133.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | TLSA |
|---|---|---|
| Share price | $2.06 | $1.05 |
| Market cap | $138.32M | $133.62M |
| 1-day change | -14.17% | 0.00% |
| YTD return | +8.99% | -29.53% |
| 1-year return | +17.05% | -46.15% |
| 5-year return | -82.60% | -30.46% |
| EPS (TTM) | $-0.38 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | — |
| Revenue growth (YoY) | +7332.76% | — |
| Net income (latest FY) | $-17.61M | $-11.86M |
| Operating margin | -279.48% | — |
| Net margin | -229.56% | — |
| 52-week high | $4.85 | $2.10 |
| 52-week low | $1.30 | $0.76 |
| Distance from 52-week high | -57.53% | -50.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +381.07% | +667.62% |
| Average volume | 286.63K | 764.91K |
| Shares outstanding | 67.14M | 127.26M |
| Employees | 128 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed TLSA by 63.2 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
ADAG vs TLSA FAQ
Which is bigger, Adagene or Tiziana Life Sciences?
Adagene (ADAG) is larger, with a market capitalization of $138.32M compared with $133.62M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, ADAG or TLSA?
ADAG returned +17.05% over the past 12 months, compared with -46.15% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.